AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Long-term Observational Study Evaluating the Presentation and Management of Acute Respiratory Tract Infections in Primary Care Across Europe

Recruitingn/aAges any - anyAllEuropean Clinical Research Alliance for Infectiou…
💬

In plain words

What the trial is, and whether it could suit you

Acute respiratory infection (ARI) is the commonest reason for consulting in community care. Furthermore, new and re-emerging pathogens are often first noticed in primary care (PC). The POS-ARI-PC study is a long-term study, with the aim of describing the nature of ARI in adults and children presenting to PC across Europe. The POS-ARI-PC study will provide critically important data on the presentation and management of ARI, and build a research-ready infrastructure for studies related to the treatment, diagnosis, and prevention of ARI in primary care settings. Additional observational studies will be embedded and use the infrastructure developed in POS-ARI-PC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
POS-ARI-PC AUDIT: Inclusion Criteria: Eligible patients will be of any age consulting (telephone, video, face-to-face) with a participating health care facility with: * Symptoms suggestive of an acute lower RTI with cough as predominant symptom and with illness duration less than 28 days, AND/OR * Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as predominant symptom and with illness duration of less than 14 days AND/OR * Patients otherwise suspected of COVID-19, influenza or RSV. Exclusion Criteria: Patients will not be eligible for if they have withdrawn their consent for anonymous data collection for research by their health care facility. POS-ARI-PC CORE: Inclusion criteria: Eligible patients will be of any age consulting (telephone, video, face to face) with a participating primary health care facility with: * Symptoms suggestive of an acute lower respiratory infection with cough as the predominant symptom, with illness duration less than 28 days, AND/OR * Symptoms suggestive of an acute upper respiratory infection with sore throat and/or coryza as the predominant symptom, with illness duration of less than 14 days AND/OR * Other symptoms suggestive of COVID-19, Influenza, RSV AND * Participant or legal guardian(s) willing and able to provide informed consent and comply with study procedures Exclusion criteria: Patients will not be eligible if: * According to the judgement of the recruiting clinician, they will not be able comply with study procedures, for example because they do not understand the language in which the study is being conducted locally (and have no one to help and translate for them); have a serious psychiatric disorder; or are terminally ill * Symptoms of presumed non-infective origin * Participant requires admission to hospital on the day of inclusion Additional in/exclusion criteria might apply to embedded studies and will be described in the SSA or ISA. POS-ARI-PC-001: Symptoms and Duration Symptoms suggestive of an acute lower RTI with new or increased cough as the predominant symptom, with illness duration ≤10 days; AND/OR Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as the predominant symptom, with illness duration ≤10 days; Age Aged 60 years and over OR Aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme; Consent Willing and able to provide informed consent and have a swab taken. Exclusion Criteria: As per the POS-ARI-PC CORE Protocol, with one exception: patients needing hospitalisation can be recruited into the study if timing allows. Patients can provide a swab and decide not to participate in the follow-up procedures.
💊

What it tests

  • Not listed
📍

Where

3 sites
Universiteit Antwerpen
Antwerp, Belgium
Centre Hospitalier Universitaire de Limoges
Limoges, France
University of Oxford
Oxford, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy